Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine

Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study

“…The differences in the findings of these two studies may relate to a number of factors, including the basal-bolus regimen used, the study population of people with newly diagnosed diabetes with presumably significant b-cell reserve, the differing ethnicity and culture of the two study populations, differences in the duration of the two studies (2-3 weeks vs. 24 weeks) and the duration of the CGM traces (48 h vs. 120 h for the INITIATION cohort). Similar factors may also explain differences in findings of a longitudinal study by Wang et al using glargine and NPH insulin [21] and Ohta et al using aspart and glulisine [22], who report a reduction in glycaemic variability, as reflected by standard deviation. Other larger studies [23] report crosssectional glycaemic variability data only in subjects with Type 2 diabetes treated with and without insulin, or recruited subjects with Type 2 diabetes who were already managed with insulin at baseline, before randomization to different regimens [24].…”

“…using glargine and NPH insulin and Ohta et al . using aspart and glulisine , who report a reduction in glycaemic variability, as reflected by standard deviation. Other larger studies report cross‐sectional glycaemic variability data only in subjects with Type 2 diabetes treated with and without insulin, or recruited subjects with Type 2 diabetes who were already managed with insulin at baseline, before randomization to different regimens .…”

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

“…Insulin aspart has also demonstrated an improved PD profile in people with T2D [ 44 , 55 , 56 ]. In one double-blind, crossover study, 25 patients with T2D received either insulin aspart immediately before a meal, or RHI administered either 30 min prior to or immediately before a meal [ 55 ].…”

“…With the rationale that postprandial administration might allow for better matching insulin dose to actual carbohydrate intake, CGM in a hospital setting was used to compare PPG excursions with preprandial insulin aspart or postprandial insulin glulisine in 12 patients with T2D, all using insulin glargine once daily at bedtime [ 56 ]. Results indicated that multiple daily injections of either insulin aspart (−10 to 0 min) or insulin glulisine (0 to 5 min) resulted in similar daily BG excursions.…”

Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes

“…Glu is a rapidacting insulin analogue that mimics the sharp rise of physiological postprandial insulin secretion more closely than regular human insulin and other insulin analogues [14]. In addition, Glu might be applied both pre-and post-meal status, providing patients with more flexibility regarding meal content and timing [15]. In patients with T2DM, multiple trials, including observational studies, have demonstrated that Glu (combined with insulin glargine or OADs) is superior to regular human insulin in terms of glycemic control, patient satisfaction and quality of life.…”